Drug Patents owned by Taiho Oncology

1. Drug name - LONSURF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9527833 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(11 years from now)

US10457666 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(11 years from now)

EP3012255A4 TAIHO ONCOLOGY Stabilized Crystal Of Tipiracil Hydrochloride, And Crystallization Method For Same
Jun, 2034

(11 years from now)

EP3012255B1 TAIHO ONCOLOGY Stable Crystal Form Of Tipiracil Hydrochloride And Crystallization Method For The Same
Jun, 2034

(11 years from now)

EP3012255A1 TAIHO ONCOLOGY Stable Crystal Form Of Tipiracil Hydrochloride And Crystallization Method For The Same
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46284 TAIHO ONCOLOGY Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor Sep, 2029

(6 years from now)

US10456399 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment Feb, 2037

(14 years from now)

US10960004 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment Feb, 2037

(14 years from now)

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

Treatment: Treatment of adults with metastatic gastric or gja previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropiate, her2/neu-targeted therapy; treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy; Method of treating cancer by detecting a creatinine clearance of a patient and administering lonsurf

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 6.14MG BASE;15MG TABLET;ORAL Prescription
EQ 8.19MG BASE;20MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.